HRAS and rhabdomyosarcoma: Because this alternative prenylation did not affect HRAS [99], FTI treatment in HRAS-driven cancers has shown promise in preclinical models of thyroid cancer, rhabdomyosarcoma, and head and neck squamous cell carcinoma [100–102], and has recently entered multiple clinical trials for different HRAS-mutant cancers [103].